Stephen E. Wolverton

820 total citations
21 papers, 320 citations indexed

About

Stephen E. Wolverton is a scholar working on Pathology and Forensic Medicine, Pharmacology and Immunology. According to data from OpenAlex, Stephen E. Wolverton has authored 21 papers receiving a total of 320 indexed citations (citations by other indexed papers that have themselves been cited), including 7 papers in Pathology and Forensic Medicine, 6 papers in Pharmacology and 6 papers in Immunology. Recurrent topics in Stephen E. Wolverton's work include Drug-Induced Adverse Reactions (6 papers), Autoimmune Bullous Skin Diseases (5 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). Stephen E. Wolverton is often cited by papers focused on Drug-Induced Adverse Reactions (6 papers), Autoimmune Bullous Skin Diseases (5 papers) and Psoriasis: Treatment and Pathogenesis (4 papers). Stephen E. Wolverton collaborates with scholars based in United States. Stephen E. Wolverton's co-authors include Julie Harper, Megan N. Landis, Gary A. Bellus, John N. Eble, Antoinette F. Hood, Kevin C. Halling, Karen E. Warschaw, Marshall B. Kapp, Vidhi Shah and Navid Ezra and has published in prestigious journals such as Journal of the American Academy of Dermatology, American Journal of Clinical Dermatology and Dermatologic Clinics.

In The Last Decade

Stephen E. Wolverton

20 papers receiving 308 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Stephen E. Wolverton United States 9 112 86 73 56 44 21 320
Stefano Dastoli Italy 13 221 2.0× 132 1.5× 54 0.7× 65 1.2× 70 1.6× 33 484
M‐A Richard France 8 182 1.6× 274 3.2× 80 1.1× 47 0.8× 83 1.9× 13 416
Ivan Grozdev Bulgaria 12 196 1.8× 292 3.4× 47 0.6× 40 0.7× 73 1.7× 19 480
S. Gómez-Bernal Spain 9 113 1.0× 114 1.3× 37 0.5× 55 1.0× 69 1.6× 21 271
Narumol Silpa‐archa Thailand 15 208 1.9× 198 2.3× 55 0.8× 56 1.0× 105 2.4× 46 461
Alin Codruț Nicolescu Romania 13 138 1.2× 178 2.1× 35 0.5× 52 0.9× 27 0.6× 45 373
Huiqun Ma China 8 159 1.4× 250 2.9× 37 0.5× 38 0.7× 41 0.9× 14 389
Leonardo Pescitelli Italy 12 177 1.6× 217 2.5× 29 0.4× 101 1.8× 59 1.3× 40 443
Ya‐Chu Tsai Taiwan 10 182 1.6× 229 2.7× 42 0.6× 60 1.1× 50 1.1× 16 376
Sree S. Kolli United States 10 174 1.6× 117 1.4× 26 0.4× 29 0.5× 13 0.3× 23 379

Countries citing papers authored by Stephen E. Wolverton

Since Specialization
Citations

This map shows the geographic impact of Stephen E. Wolverton's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Stephen E. Wolverton with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Stephen E. Wolverton more than expected).

Fields of papers citing papers by Stephen E. Wolverton

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Stephen E. Wolverton. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Stephen E. Wolverton. The network helps show where Stephen E. Wolverton may publish in the future.

Co-authorship network of co-authors of Stephen E. Wolverton

This figure shows the co-authorship network connecting the top 25 collaborators of Stephen E. Wolverton. A scholar is included among the top collaborators of Stephen E. Wolverton based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Stephen E. Wolverton. Stephen E. Wolverton is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Wolverton, Stephen E.. (2020). Comprehensive Dermatologic Drug Therapy. Elsevier eBooks. 65 indexed citations
2.
Wolverton, Stephen E.. (2019). Advances in Diagnosis and Management of Cutaneous Adverse Drug Reactions: Current and Future Trends. American Journal of Clinical Dermatology. 20(4). 605–606. 5 indexed citations
3.
Shah, Vidhi, Marshall B. Kapp, & Stephen E. Wolverton. (2016). Medical Malpractice in Dermatology—Part I: Reducing the Risks of a Lawsuit. American Journal of Clinical Dermatology. 17(6). 593–600. 3 indexed citations
4.
Wolverton, Stephen E.. (2016). Practice Gaps. Dermatologic Clinics. 34(3). 311–318. 2 indexed citations
5.
Shah, Vidhi, Marshall B. Kapp, & Stephen E. Wolverton. (2016). Medical Malpractice in Dermatology—Part II: What To Do Once You Have Been Served with a Lawsuit. American Journal of Clinical Dermatology. 17(6). 601–607.
6.
Ezra, Navid, et al.. (2016). Multiple keratoacanthomas occurring in surgical margins and de novo treated with intralesional methotrexate.. PubMed. 98(6). E12–E15. 5 indexed citations
7.
Wolverton, Stephen E. & Julie Harper. (2013). Important Controversies Associated with Isotretinoin Therapy for Acne. American Journal of Clinical Dermatology. 14(2). 71–76. 26 indexed citations
8.
Wolverton, Stephen E.. (2012). Comprar Comprehensive Dermatologic Drug Therapy, 3rd Edition | Stephen E. Wolverton | 9781437720037 | Saunders. 4 indexed citations
9.
Landis, Megan N., et al.. (2011). Immunosuppression and sebaceous tumors: A confirmed diagnosis of Muir-Torre syndrome unmasked by immunosuppressive therapy. Journal of the American Academy of Dermatology. 65(5). 1054–1058.e1. 20 indexed citations
10.
Wolverton, Stephen E., et al.. (2010). Recent Trends in Systemic Psoriasis Treatment Costs. Archives of Dermatology. 146(1). 46–54. 71 indexed citations
11.
Wolverton, Stephen E.. (2009). Controversies in Dermatologic Drug Therapy. Dermatologic Therapy. 22(5). 397–397. 2 indexed citations
12.
Wolverton, Stephen E.. (2009). Can short courses of systemic corticosteroids truly cause osteonecrosis?. Dermatologic Therapy. 22(5). 458–464. 5 indexed citations
13.
Wolverton, Stephen E., et al.. (2009). Moxifloxacin-induced drug hypersensitivity syndrome with features of toxic epidermal necrolysis.. PubMed. 8(11). 1031–3. 7 indexed citations
14.
Wolverton, Stephen E., et al.. (2007). Suggested Guidelines for Patient Monitoring: Hepatic and Hematologic Toxicity Attributable to Systemic Dermatologic Drugs. Dermatologic Clinics. 25(2). 195–205. 25 indexed citations
15.
Wolverton, Stephen E., et al.. (2007). The efficacy and safety of rituximab in refractory pemphigus: a review of case reports.. PubMed. 6(9). 883–9. 13 indexed citations
16.
Warschaw, Karen E., John N. Eble, Antoinette F. Hood, Stephen E. Wolverton, & Kevin C. Halling. (1997). The Muir‐Torre syndrome in a black patient with AIDS: histopathology and molecular genetic studies. Journal of Cutaneous Pathology. 24(8). 511–518. 17 indexed citations
17.
Wolverton, Stephen E.. (1997). Update on cutaneous drug reactions.. PubMed. 13. 65–84. 9 indexed citations
18.
Wolverton, Stephen E.. (1995). Major adverse effects from systemic drugs: Defining the risks. Current Problems in Dermatology. 7(1). 6–38. 8 indexed citations
19.
Wolverton, Stephen E.. (1992). Monitoring for adverse effects from systemic drugs used in dermatology. Journal of the American Academy of Dermatology. 26(5). 661–679. 25 indexed citations
20.
Wolverton, Stephen E.. (1991). Systemic Drug Therapy for Psoriasis. Archives of Dermatology. 127(4). 565–565. 5 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026